microRNA-297 (miR-297)

microRNA-297 is a small, endogenous non-coding RNA molecule, approximately 22 nucleotides in length, that functions as a post-transcriptional regulator of gene expression in human cells[5][6]. It acts by binding to complementary sequences, primarily in the 3′-UTR regions of target mRNAs, promoting mRNA degradation or inhibiting translation. miR-297 is involved in several key processes in cancer biology, including regulation of cell proliferation, migration, invasion, and drug resistance. For example, in hepatocellular carcinoma, miR-297 suppresses tumor progression partly by targeting the polypyrimidine tract-binding protein 3 (PTBP3) and inhibiting the PI3K/AKT signaling pathway[1]. In colorectal cancer, reduced miR-297 leads to increased MRP-2 levels and multidrug resistance[3]. While not a receptor, enzyme, or channel, miR-297 is considered a therapeutic target because of its modulatory role in various disease-relevant pathways and its potential as a disease biomarker.

Other names

hsa-miR-297MIR297MIRN297

Not a direct drug target; instead, acts as a negative regulator of gene expression by binding 3′-UTRs of mRNAs, leading to mRNA degradation or translation inhibition[1][5][3]. As a therapeutic target, modulation (mimics or antagomirs) of miR-297 could alter cancer cell sensitivity or resistance to drugs via post-transcriptional gene regulation[3][1].